King Pharmaceuticals Income Statement
View: Annual | Quarterly
| Dec 07 | Dec 06 | Dec 05 | |
|---|---|---|---|
| Revenue | 2,136.9 | 1,988.5 | 1,772.9 |
| Cost of Goods Sold | 566.5 | 419.8 | 323.0 |
| Gross Profit | 1,570.3 | 1,568.7 | 1,449.9 |
| Gross Profit Margin | 73.5% | 78.9% | 81.8% |
| SG&A Expense | 1,166.9 | 1,015.7 | 1,119.7 |
| Depreciation & Amortization | 175.9 | 150.4 | 150.1 |
| Operating Income | 227.5 | 402.5 | 180.1 |
| Operating Margin | 10.6% | 20.2% | 10.2% |
| Nonoperating Income | 31.1 | 31.6 | 10.0 |
| Nonoperating Expenses | 7.8 | 9.9 | 11.9 |
| Income Before Taxes | 250.8 | 424.3 | 178.1 |
| Income Taxes | 67.6 | 135.7 | 61.5 |
| Net Income After Taxes | 183.2 | 288.6 | 116.6 |
| Continuing Operations | 183.2 | 288.6 | 116.6 |
| Discontinued Operations | (0.2) | 0.4 | 1.2 |
| Total Operations | 183.0 | 289.0 | 117.8 |
| Total Net Income | 183.0 | 289.0 | 117.8 |
| Net Profit Margin | 8.6% | 14.5% | 6.6% |
| Diluted EPS from Total Net Income ($) | 0.75 | 1.19 | 0.49 |
| Dividends per Share | -- | -- | -- |






